HOME >> BIOLOGY >> NEWS
AAAS denounces anti-evolution laws as hundreds of K-12 teachers convene for 'Front Line' event

ST. LOUIS, MO.--The Board of Directors of the world's largest general scientific organization, the American Association for the Advancement of Science (AAAS), today strongly denounced legislation and policies that would undermine the teaching of evolution and "deprive students of the education they need to be informed and productive citizens in an increasingly technological, global community."

Across the United States, at least 14 pending laws -- including Missouri HB 1266 -- differ in language and strategy, but "all would weaken science education," said AAAS President Gilbert S. Omenn, professor of medicine, genetics and public health at the University of Michigan, Ann Arbor. "The AAAS Board of Directors opposes these attacks on the integrity of science and science education," he added. "They threaten not just the teaching of evolution, but students' understanding of the biological, physical, and geological sciences."

Pending U.S. anti-evolution legislation currently includes: Alabama HB 016/ SB 45, Michigan HB 5251, Michigan HB 5606, Missouri HB 1266, Mississippi SB 2427, Mississippi HB 953, New York A 8036, Oklahoma SB 1959, Oklahoma HB 2107, Oklahoma HCR 1043, South Carolina S 909 and Utah SB 96

Some of these bills would seek to discredit evolution by emphasizing "flaws" in the theory of evolution, or "disagreements" within the scientific community, the AAAS Board noted. Other bills would encourage teachers and students to explore the concept of intelligent design or other non-scientific "alternatives" to evolution, or to "critically analyze" evolution and "the controversy". But, AAAS emphasized, "There is no significant controversy within the scientific community about the validity of evolution."

Moreover, "Evolution is one of the most robust and widely accepted principles of modern science," the AAAS Board concluded, reconfirming its October 18, 2002 statement,
'"/>


19-Feb-2006


Page: 1 2 3 4

Related biology news :

1. New egg freezing technique offers hope to hundreds of women
2. Expedition allows teachers to participate in polar research
3. High school students, teachers join Pitts Gene Team
4. APS awards more than $150,000 in fellowships to middle and high school science teachers
5. From research labs to the schools: Science teachers bring summer science to the classroom
6. Developed/emerging market biotech firms convene at largest-ever meeting with global health focus
7. Research physiologists convene for 120th Annual Meeting
8. Europes leading life science researchers are to convene for the first annual EuroBioForum
9. Environmental toxicology experts to convene at Penn symposium
10. USC and AAAS/Science convene leading innovators to discuss challenges to US preeminence
11. 20th annual convention of US naturopathic physicians convenes Aug. 24, 2005 in Phoenix

Post Your Comments:
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: